Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The investigators plan to evaluate the efficacy and safety of intranasal Ketalar (ketamine
hydrochloride) in the treatment of primary symptom manifestations of pediatric bipolar
disorder; Fear of Harm (FOH) phenotype. This phenotype represents those children who are most
resistant to traditional treatments and suffer repeated hospitalizations. Primary symptoms
include fearfulness, aggression secondary to threat, mood and/or arousal instability, and
psychosis. In addition to evaluation of efficacy and safety, the investigators will also
analyze whether therapeutic response depends upon the degree to which the subject fits the
FOH phenotype.